This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:tests:lipids [10.23.2010] – paulalbert | home:tests:lipids [01.03.2012] – external edit 127.0.0.1 | ||
---|---|---|---|
Line 7: | Line 7: | ||
* triglycerides | * triglycerides | ||
- | In many of the diseases the Marshall Protocol (MP) treats, patients may present with elevated cholesterol. Traditionally, | + | In many of the diseases the Marshall Protocol (MP) treats, patients may present with elevated cholesterol. Traditionally, |
Both " | Both " | ||
+ | |||
+ | |||
+ | |||
+ | [{{ : | ||
+ | |||
+ | |||
Thus, high cholesterol levels among patients on the MP are not seen as a problem but as a sign of the inflammatory response to infection. This means that MP patients do not need to take any measures to lower cholesterol. Over time, as the MP medications work to gradually lower infectious agents causing inflammation, | Thus, high cholesterol levels among patients on the MP are not seen as a problem but as a sign of the inflammatory response to infection. This means that MP patients do not need to take any measures to lower cholesterol. Over time, as the MP medications work to gradually lower infectious agents causing inflammation, | ||
Line 22: | Line 28: | ||
Both " | Both " | ||
- | There is also broad evidence that cholesterol does not promote plaque as evidenced by studies that show therapies which directly lower cholesterol may make patients sicker. The article devoted to [[home: | + | There is also broad evidence that cholesterol does not promote plaque as evidenced by studies that show therapies which directly lower cholesterol may make patients sicker. The article devoted to [[home: |
Some patients on the Marshall Protocol (MP) have reported temporary increases in cholesterol and triglycerides, | Some patients on the Marshall Protocol (MP) have reported temporary increases in cholesterol and triglycerides, | ||
--></ | --></ | ||
- | |||
- | [{{ : | ||
- | |||
===== Statins and other anti-cholesterol drugs ===== | ===== Statins and other anti-cholesterol drugs ===== | ||
- | < | + | < |
{{section>: | {{section>: | ||
Line 122: | Line 125: | ||
</ | </ | ||
===== Notes and comments ===== | ===== Notes and comments ===== | ||
- | TECHEDIT | + | |
* Legacy content | * Legacy content | ||
Line 128: | Line 131: | ||
+ | < | ||
+ | |||
+ | http:// | ||
+ | |||
+ | Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+-year olds | ||
+ | Abstract | ||
+ | |||
+ | People aged 80 or older are the fastest growing population in high-income countries. One of the most common causes of death among the elderly is the cardiovascular disease (CVD). Lipid-lowering treatment is common, e.g. one-third of 75–84-year-old Swedes are treated with statins [ 3]. The assumption that hypercholesterolaemia is a risk factor at the highest ages seems to be based on extrapolation from younger adults. A review of observational studies shows a trend where all-cause mortality was highest when total cholesterol (TC) was lowest (‘a reverse J-shaped’ association between TC and all-cause mortality). Low TC (<5.5 mmol/l) is associated with the highest mortality rate in 80+-year olds. No clear optimal level of TC was identified. A review of the few randomised controlled trials including 80+-year olds did not provide evidence of an effect of lipid-lowering treatment on total mortality in 80+-year-old people. There is not sufficient data to recommend anything regarding initiation or continuation of lipid-lowering treatment for the population aged 80+, with known CVD, and it is even possible that statins may increase all-cause mortality in this group of elderly individuals without CVD.</ | ||
===== References ===== | ===== References ===== |